Crazy volatility even for a biotech with COVID19 product in the works.
Was the reading the PR news on this one this week, since I take an RA drug.....
I was thinking 2 weeks ago, based on my Bio-engineering-Bio-Chem back ground (my older brother mentor was an MD) that RA drugs, Immune suppressants might just limit the COVID19 damage, if I got unlucky and caught it.
Problem is taking it makes me an easy target for COVID19, but taking it protects my joints (I have the RA version of arthritis, bad shit), and may just limit lung damage since most of the Covid19 damage is done by the immune systems over response of trying to kill the virus.
That PR this week got my attention (COvid19/Biotech news) and bang there is, the big boys thinking the same thing I was.
Which reminds me that VEP-Lipsome in a drink by Milv has solid potential for limiting and repair lung cell tissue damage from Covid19 as well. Hang on to those shares tight sir, as the past research says I am right, so if Milv/NDT Pharma comes out with a covid19 supplement drink line approved by UPennMed doctors (the JV partners with Milv) that price could explode 50 fold in days.
I hope to interview management (ungaged management) in a week or so and report back to folks since the Custodian was relieved today, from what I heard(??)
All of my posts are strictly opinions and should not be considered to be facts, or investment advise. They are for entertainment purposes only.
